BRD4 and cancer: As expected, the resultingAPC 13 (Table 1, entry 13) showed comparable BRD4 degradation with the parentalPROTAC (APC 13, DC50 = 22 nM, Dmax > 90% vs parental PROTAC DC50 = 13 nM, Dmax > 90%) in highly nucleolin-expressingMCF-7breast cancer cells.67